A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Praliciguat ([14C]-IW-1973) Following a Single Oral Dose in Healthy Male Subjects
Latest Information Update: 20 Jun 2019
At a glance
- Drugs Praliciguat (Primary)
- Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure
- Focus Pharmacokinetics
- Sponsors Cyclerion Therapeutics; Ironwood Pharmaceuticals
- 18 Jun 2019 Status changed from recruiting to completed.
- 05 Mar 2019 Status changed from not yet recruiting to recruiting.
- 02 Feb 2019 New trial record